Benzhydrocodone
From Wikipedia, the free encyclopedia
 |
|
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
6,7-didehydro-4,5α-epoxy-3-methoxy-17-methylmorphinan-6-yl benzoate
|
|
| Clinical data | |
| Routes of administration |
Oral |
| Identifiers | |
| CAS Number | 1259440-61-3 |
| ChemSpider | 31484780 |
| Synonyms | KP201 |
| Chemical data | |
| Formula | C25H25NO4 |
| Molar mass | 403.470 |
| 3D model (Jmol) | Interactive image |
|
|
|
|
Benzhydrocodone (INN) (contracted from benzoate-hydrocodone) is a opioid prodrug of the morphinan class. Its chemical structure consists of hydrocodone coupled with benzoic acid. Benzhydrocodone itself is inactive and acts as a prodrug to hydrocodone upon cleavage of the benzoate portion of the molecule.[1]
It is designed to be an opioid analgesic with a low chance of recreational use.[2]
Created by a biopharmaceutical company in Coralville, Iowa. President and CEO, Travis Mickle, believes the molecular-based approach to abuse-detterent may be more effective than many formulation-based approaches.[3]
References[edit]
- ^ KemPharm, Inc. (June 11, 2013). "KemPharm, Inc. Receives Patent from the USPTO for Novel Pain Drug Candidate, KP201" (Press release). North Liberty, Iowa: PR Newswire. Retrieved February 8, 2015.
- ^ Lavitt, John (June 12, 2014). "New Abuse-Resistant Opioid Receives $60 Million Backing". http://thefix.com/. The Fix. Retrieved February 8, 2015. External link in
|website=(help) - ^ "KP201/APAP". http://www.kempharm.com/. Retrieved April 20, 2015. External link in
|website=(help)
 |
This analgesic-related article is a stub. You can help Wikipedia by expanding it. |
